FDA PMA FDA Class 3 Approved 🇺🇸 United States

Cancer-Related Germline Gene Mutation Detection System

PMA: P140020 · Decision Dec 19, 2014
Classifications
1
FEI Numbers
1
Registration Numbers
1

Basic Information

Device Name
Cancer-Related Germline Gene Mutation Detection System
Trade Name
BRACANALYSIS CDX
PMA Number
P140020
Device Class
FDA Class 3
Product Code
PJG
Generic Name
Cancer-related germline gene mutation detection system
Medical Specialty
Unknown
Advisory Committee
Pathology
Decision
Approved
Decision Code
APPR
Decision Date
December 19, 2014
Date Received
September 24, 2014
Expedited Review
Y
Docket Number
14M-2248

Advisory Committee Statement

APPROVAL FOR THE BRACANALYSIS CDX. THIS DEVICE IS INDICATED AS FOLLOWS: BRACANALYSIS CDX IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION AND CLASSIFICATION OF VARIANTS IN THE PROTEIN CODING REGIONS AND INTRON/EXON BOUNDARIES OF THE BRCA1 AND BRCA2 GENES USING GENOMIC DNA OBTAINED FROM WHOLE BLOOD SPECIMENS COLLECTED IN EDTA. SINGLE NUCLEOTIDE VARIANTS AND SMALL INSERTIONS AND DELETIONS (INDELS) ARE IDENTIFIED BY POLYMERASE CHAIN REACTION (PCR) AND SANGER SEQUENCING. LARGE DELETIONS AND DUPLICATIONS IN BRCA1 AND BRCA2 ARE DETECTED USING MULTIPLEX PCR. RESULTS OF THE TEST ARE USED AS AN AID IN IDENTIFYING OVARIAN CANCER PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA VARIANTS ELIGIBLE FOR TREATMENT WITH LYNPARZA (OLAPARIB). THIS ASSAY IS FOR PROFESSIONAL USE ONLY AND IS TO BE PERFORMED ONLY AT MYRIAD GENETIC LABORATORIES, A SINGLE LABORATORY SITE LOCATED AT 320 WAKARA WAY, SALT LAKE CITY, UT 84108.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
PJG Cancer-Related Germline Gene Mutation Detection System